Empower Advisory Group LLC Sells 44 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Empower Advisory Group LLC lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 782 shares of the company’s stock after selling 44 shares during the period. Empower Advisory Group LLC’s holdings in IDEXX Laboratories were worth $323,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Truist Financial Corp lifted its stake in IDEXX Laboratories by 13.9% in the 4th quarter. Truist Financial Corp now owns 27,784 shares of the company’s stock valued at $11,487,000 after acquiring an additional 3,382 shares in the last quarter. CIBC Asset Management Inc lifted its stake in IDEXX Laboratories by 3.1% in the 4th quarter. CIBC Asset Management Inc now owns 26,366 shares of the company’s stock valued at $10,901,000 after acquiring an additional 788 shares in the last quarter. J.W. Cole Advisors Inc. lifted its stake in IDEXX Laboratories by 4.5% in the 4th quarter. J.W. Cole Advisors Inc. now owns 2,760 shares of the company’s stock valued at $1,141,000 after acquiring an additional 118 shares in the last quarter. Blue Zone Wealth Advisors LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $3,958,000. Finally, Sheaff Brock Investment Advisors LLC lifted its stake in IDEXX Laboratories by 1.7% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 3,036 shares of the company’s stock valued at $1,255,000 after acquiring an additional 51 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Piper Sandler boosted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Finally, Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Stock Performance

IDXX opened at $450.99 on Thursday. The business has a fifty day simple moving average of $430.91 and a 200 day simple moving average of $452.43. The company has a market capitalization of $36.93 billion, a PE ratio of 42.27, a price-to-earnings-growth ratio of 3.35 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares in the company, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock worth $6,161,276 in the last ninety days. 2.18% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.